Shooting for the STARS
Entering the Dawn of Unprecedented Breakthroughs in Life Sciences & Medicine

BioPacific Conference 2016 太平洋生物大会
18th CABS Annual Conference
May 7th, Saturday, 2016, 8:00AM-9:00PM
San Mateo Marriott, 1770 South Amphlet Blvd., San Mateo, CA 94402
Our Mission

• To serve biopharmaceutical professionals with interests in China and promote interactions locally and across the Pacific
  为有意在中国创业经商的专业人士提供本地及跨太平洋的合作机会
• To foster business opportunities and exchanges in the life science industry between the U.S. and China
  促进中美生物医药交流和商业合作
• To promote public awareness of progress and development in the pharmaceutical and biotechnological industry
  提高公众对生物技术及制药行业新进展的了解
• To collaborate with other organizations in areas of mutual interest
  与其它机构和组织发展互利合作关系
TABLE OF CONTENTS

2 BioPacific Conference 2016 Sponsors and Partners
3 Our Mission CABS Contact Information
4 Table of Contents
6 CABS Leadership
7 2016 BioPacific Conference Organizing Committee
8 About CABS
9 Remarks from the President of CABS
10 CABS Membership Facts
11 Inaugural BioPacific Partnering Forum
12 BioPacific Conference 2016 Agenda
14 Speakers
   Gerald Chan, Sc.D.
   Hari Kumar, Ph.D.
   Piers Whitehead
   Robert Lou
   Hui Zhang,
   Jinqun Yin, MBA
   Mark Selby, Ph.D.
   Stanley Lei Qi, Ph.D.
   Darren Ji, M.D., Ph.D., MBA
   Charles Comey, J.D.
   Thomas L. Irving, J.D.
   Wen Li, Ph.D.
   Shawn Qian, Ph.D.
Xian-Ping Lu, Ph.D.
Dan Zhang, M.D., Ph.D.
Xiaodong Yang, M.D., Ph.D.
Cheni Kwok, Ph.D., CLP
Connie Sun, Ph.D.
Steven Adams, DVM, Ph.D.
Min Cui, Ph.D.
Alexis Ji, Ph.D., MBA
Shawn Lee, Ph.D.
Cheng Liu, Ph.D.
Vincent Liu, Ph.D.
Yuwen Liu
James Zhao, M.D.
Jennifer Hu, Ph.D.

35 2016 CABS K. Fong Award in Life Sciences

38 CABS Activities 2015 – 2016
Highlight of Past Events with Our Partners
Science & Technology Programs
Business & Career Development
International Collaboration
Social Life
Membership

50 Advertisements

63 CABS Membership/Sponsorship Benefits

*The official working language of the conference is English
CABS Leadership

Board of Directors
Alan Hao, Ph.D.
Jing Shan Hu, Ph.D.
Leping Li, Ph.D.
Shichang Miao, Ph.D.
Zhonghua Pei, Ph.D.
Jun Xiang, Ph.D.
Janet Xiao, Ph.D., J.D.
Naibo Yang, Ph.D.
Wentao Zhang, Ph.D.

Advisory Board
Wei Dong, M.D., Ph.D.
Baolu Chen, Ph.D.
Keting Chu, M.D., Ph.D.
John Wang, Ph.D.
Guoliang Yu, Ph.D.
Cheng Li, Ph.D.
DQ Wang, Ph.D.
Yingfei Wei, Ph.D.

2016 Executive Council
President
Jiangwen Majeti, Ph.D., M.B.A.
Roche/Genentech
President-Elect
Cheni Kwok, Ph.D., CLP,
Linear Dreams
Past President
Xiaolin Alan Hao, Ph.D.,
AIM Biosciences Inc.
Treasurer
David Wang, B.S., C.P.A.
Bookkeeper
Yao Long, B.S. Epitomics, Inc.

Business & Career Development
Co-chairs
Jessica Sun, Ph.D. Reset Therapeutics
Alex J. Zhang, Ph.D. Enverest, Inc.
Elected Members
Tim Tian, Ph.D. CelloBio Inc.
Appointed Members/Volunteers
Ting Jia, Ph.D. Jiangsu Hengrui Medicine
Shenshen Hu, Ph.D. UC Berkeley

Fundraising
Co-chairs
Jianlong Lou, Ph.D. UCSF
Gavin Lu, Ph.D. Eureka Therapeutics Inc.
Elected Members
Charles Chen, Ph.D. Bellen Chemistry
Norman Zhou, Ph.D. Genentech
Appointed Members/Volunteers
Li-Ming Liang, Ph.D. Nexcelom Bioscience

International Collaboration
Co-chairs
Yan Wang, Ph.D. Gazelle Technologies
Wei Zhang, Ph.D. Robotic Medsystems
Elected Members
Dannis Chang, Ph.D. Genentech
Appointed Members/Volunteers
Hao Wu, Ph.D. UCSF
Lingjie Guan, Ph.D. Bayer

Membership
Co-chairs
Liping Meng, Ph.D. Gilead Sciences
Yonghua Pan, Ph.D.
Sangamo Biosciences
Elected Members
Yan Qi, Ph.D. Morrison & Foerster LLP
Lin Yan, Ph.D. Applied StemCells, Inc.

Operations
Chair
Carrie Kaiyue Wang, M.D.
Concept to Clinic
Elected Members
Zhican Wang, Ph.D. Amgen
Appointed Members/Volunteers
Yang Du, Ph.D. Stanford

Publication & Communication
Co-chairs
Zhenhai Shen, Ph.D. Genentech
Yang Tian, Ph.D. Gilead Sciences
Elected Members
Jieyi Wang, Ph.D. Abbvie
Eva Wang, Ph.D. HTG Molecular Dx
Xiang Wang, Ph.D. Denali Therapeutics

Science & Technology
Co-chairs
Ann Mongan, Ph.D.
Thermo Fisher Scientific
Jiwen (Jim) Liu, Ph.D. RIFA Pharma, Inc.
Elected Members
Taotao Chen, Ph.D. Bayer
Luqia Hou, Ph.D. Stanford

Social Life
Co-chairs
Sihong Zhou, Sutro Biopharma
Jian (Ken) Zhang, Ph.D. Pharmacyclics
Elected Members
Lynn Guo, Ph.D. Genentech
2016 Biopacific Conference Organizing Committee

- Cheni Kwok, Ph.D., CLP, 2016 BioPacific Conference Chair; CABS President-Elect; Managing Partner, Linear Dreams
- Jiangwen Majeti, Ph.D., MBA, President CABS; Global Category Manager, Biomarker and CDx, Roche/Genentech
- Carrie Kaiyue Wang, M.D., CABS Operations Chair, Pre-clinical/Toxicology, Concept to Clinic
- Gavin (Jingwei) Lu, Co-Chair CABS Fundraising Committee; Research Scientist, Eureka Therapeutics
- Jianlong Lou, Co-Chair, CABS Fundraising Committee; Associate Professor, UCSF
- Yang Tian, Ph.D., Co-Chair, CABS Publication Committee; Research Scientist, Gilead
- Zhenhai Shen, Ph.D., MBA, Co-Chair CABS Publication Committee; Director, Research Service Procurement, Global Pharma Procurement, Genentech
- Liping Meng, Ph.D., Co-Chair CABS Membership Committee; Research Scientist Gilead
- Yonghua Pan, Ph.D., Co-Chair CABS Membership Committee; Scientist, Sangam BioSciences
- Yan Wang, Ph.D., Co-Chair, CABS International Collaboration Committee; Vice President, Business Development, Gazelle Technologies
- Wei Zhang, Ph.D., Co-Chair, CABS International Collaboration, Project Manager, HBI Solutions
- Alex J. Zhang, Ph.D., MBA, Co-Chair CABS Business and Career Development Committee; Managing Partner, Enverest
- Jessica Sun, Ph.D., Co-Chair CABS Business and Career Development Committee; Director, In Vivo Biology; Reset Therapeutics
- Hao Wu, Ph.D., CABS International Collaboration Committee, Associate Specialist, UCSF
- Alexis Ji, Ph.D., MBA, Principal, WuXi Healthcare Ventures
- Shawn Qian, Ph.D., Co-Founder, Chief Executive Officer & President, NeuPharma
- Sihong Zhou, Ph.D. Co-Chair CABS Social Life Committee; Sutro Biopharma
- Jian (Ken) Zhang, Ph.D. Co-Chair CABS Social Life Committee; Pharmacyclics

Special Acknowledgements:

- 2015-2016 CABS Operations, Executive Committees and volunteers
- Ken Fong, Ph.D., Founder and Chairman, Kenson Ventures LLC
- Wentao Zhang, Ph.D., CABS BOD, Founder, Quintara Discovery
- Ruhong Jiang, Ph.D., CEO & President, Applied Stem Cells
- Charlene Liao, Ph.D., Project Team Leader, Genentech
- Shichang Miao, Ph.D., Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc.
- Mohan Srinivasan, Director, Protein Chemistry, Bristol-Myers Squibb
- Connie Sun, Ph.D., SVP, Business & Corporate Development, Pharmaron
- Minli Xie, Ph.D., Senior Director, Medivation
- Naibo Yang, Ph.D., Director, Immunogenetics at Complete Genomics Inc.

Graphics and Websites:

- Xiaojun Li, Graphic Design/Website Design
- Michael Lin, Website Design & Support, Pink Trumpet Associates
About CABS

Who We Are
The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in San Francisco Bay Area, California. This is the home of the Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceuticals such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and subscribers in the life sciences industry. About 70% of our members have Ph.D. degree relating to life sciences. A considerable proportion of the members are holding senior research and management positions in American and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists or investors in the life sciences sector. CABS is the largest and most active Chinese biopharmaceutical association in Northern America. We organize many activities to promote Sino-US collaborations in life sciences and to provide Science & Technology Parks and life sciences companies in China with an excellent platform to promote business and to recruit talent. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders.

CABS Membership Demographics
Our membership consists of life science professionals from a broad range of experience levels. A large percentage of our members hold senior or executive positions in the industry, and we are proud to have numerous entrepreneurs who have successfully started and sold life science companies in our pedigree. In addition, we continue to attract new talent from the local academic institutions (UC Berkeley, UC San Francisco, and Stanford University, among others).
Welcome to the 2016 BioPacific Conference, the 18th annual conference of the Chinese American Biopharmaceutical Society (CABS)!

I would like to thank President-elect Dr. Cheni Kwok, the conference organization committee, and all the volunteers who have worked diligently for the past six months to bring you this impressive program.

The biopharmaceutical industry has been experiencing tremendous growth in recent years. We have record high FDA new drug approvals, an active IPO market, and exciting Merger and Acquisition activities. Leading in biotech investment from venture capital firms, the San Francisco Bay Area prizes itself not only as a hot bed for innovation and start-ups, but also as a magnet for talent – both of which have increasingly attracted attention from global companies including many in China. Our 18th annual conference will cover multiple aspects of these important trends.

As one of the largest non-profit biopharmaceutical professional organizations on the west coast, CABS is uniquely positioned to ride the wave of biotech/pharmaceutical success. On one hand, we continue to serve our members by providing cutting-edge and educational Science and Technology workshops and nurturing the growth of next generation professionals with career-mentoring programs. On the other hand, we actively engage companies from China to support their talent recruitment activities and investment interests for novel technologies and pharmaceutical programs. To foster greater exchange between the biotech communities in both the US and China, we continue to organize annual delegation trips to China. Taking advantage of our San Francisco location, we successfully organized the first “CABS Investor Forum 2016” at the JP Morgan conference to bridge an ongoing dialogue between investors and entrepreneurs across the Pacific Ocean.

CABS’s success is a story of a strong community with the support of many. We are honored to announce Dr. Gerald Chan as the winner of the 2016 Visionary in Life Sciences CABS K. Fong Special Award. Dr. Chan has made life-long contributions in cultivating a generation of successful entrepreneurs and life sciences companies. The spirit of generosity and outstanding leadership embodied by Dr. Chan will transpire CABS and beyond. As the president of CABS, I am extremely proud to work with colleagues in our eight executive committees and offices, whose passion and dedication make CABS a better organization every day. I am also truly appreciative of our devoted members and sponsors, who have and continue to support CABS.

Thank you for joining us. I hope you enjoy today’s program.

With warm regards,

Jiangwen Majeti, CABS President
Our LinkedIn Group has also seen continued growth over the last year and is becoming an increasingly important component in our mission of promoting public awareness of the life science industry, encouraging business opportunity and exchange, and serving as a bridge for the life science industry throughout the Asia Pacific.

URL: https://www.linkedin.com/grp/home?gid=695127  Membership as of April 20, 2016: 618
Inaugural BioPacific Partnering Forum

The 2016 BioPacific Conference brings together leaders in the life sciences community from the Pacific Rim and the United States. In order to further facilitate the interactions including project introduction and talent recruitment between our attendees and our sponsors, we are introducing a two-day BioPacific Partnering Forum in conjunction with our conference this year.

Our Sponsors:
• Three major sponsors:
  • Ningbo Kangtaibo Technology Development Co. Ltd & Ningbo Hangzhou Bay New Zone
  • Zibo National High-tech Industrial Development Zone
  • Chengdu Kanghong Pharmaceuticals Group
• All sponsors and exhibitors of 2016 BioPacific Conference

How to Participate:
• Complimentary for all attendees, sponsors and exhibitors of the 2016 BioPacific Conference
• Sign up at icc@cabsweb.org to schedule one-on-one meetings
  • Please indicate which sponsor you would like to meet along with your CV and project ppt as appropriate
  • If you are interested in meeting other sponsors, please let us know

When and Where:
• May 7 from 9am – 6pm
  Onsite at the 2016 BioPacific Conference
  One-on-one meeting
• May 8 from 10am – 5pm
  • Hanqi Investment Inc. (1633 Bayshore Hwy, Burlingame, CA 94010)
  • Featured presentations from three major sponsors; brief presentations from other participating sponsors
  • Followed by one-on-one meeting

About the Inaugural BioPacific Partnering Forum:
• Enable one-on-one discussions with BioPacific Conference sponsors and exhibitors
• Learn more about incentives for entrepreneurs at Ningbo Kangtaibo Technology Development Co. Ltd, Ningbo Hangzhou Bay New Zone and Zibo National High-tech Industrial Development Zone
• Access to senior management of Chengdu Kanghong Pharmaceuticals Group for talent recruitment and project collaboration
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am – 8:45am</td>
<td>Registration</td>
</tr>
<tr>
<td>8:45am – 8:50am</td>
<td>Welcome Remarks</td>
</tr>
<tr>
<td>8:50am – 9:00am</td>
<td>State of the Society</td>
</tr>
<tr>
<td>9:00am – 9:10am</td>
<td>CABS K. Fong Special Award: Visionary in Life Sciences</td>
</tr>
<tr>
<td>9:10am – 10:00am</td>
<td>Somewhere Between Science and Humanity</td>
</tr>
<tr>
<td>10:00am – 10:20am</td>
<td>Break</td>
</tr>
<tr>
<td>10:20am – 10:55am</td>
<td>M&amp;A: An Insider’s Perspective</td>
</tr>
<tr>
<td>10:55am – 11:30am</td>
<td>Vaccines: Lessons from the Oldest Class of Biologics</td>
</tr>
<tr>
<td>11:30am – 12:00pm</td>
<td>Life Sciences Parks in China: Growth and Trends</td>
</tr>
</tbody>
</table>
12:00pm – 1:00pm  Lunch Break

Afternoon Session I: Life Sciences Breakthroughs & Partnerships  
Session Chairs: Connie Sun, Ph.D. & Charlene Liao Ph.D.

1:00pm – 1:30pm  Chengdu Kanghong Biotech Co and Conbercept  
Jinqun Yin, MBA, Vice President, Chengdu Kanghong Pharmaceutical Group

1:30pm – 2:05pm  Immunotherapy: Past, Present and Future  
Mark Selby, Ph.D., Senior Director, Immuno-oncology, Bristol-Myers Squibb

2:05pm – 2:40pm  CRISPR/dCas9 Technology for Genome Manipulation and Disease Research  
Stanley Lei Qi, Ph.D., Assistant Professor, Department of Bioengineering and Department of Chemical and Systems Biology, Stanford University

2:40pm – 3:15pm  The Art of Partnering  
Darren Ji, M.D., Ph.D., MBA, Vice President and Global Head of Roche Partnering, Asia and Emerging Markets

3:15pm – 3:45pm  Key Trends and Case Studies: U.S. – China Cross-Border Life Sciences Investment and Strategic Cooperation  
Charles Comey, J.D., Partner, Morrison & Foerster LLP

3:45pm – 4:05pm  Coffee break

Afternoon Session II:  Trends in BioPharmaceutical Development – China & Global Considerations  
Session Chair: Shichang Miao, Ph.D. & Yang Tian, Ph.D.

4:05pm – 5:20pm  Panel Discussion: BioPharmaceutical Development - China & Global Considerations  
(Moderator: Shichang Miao, Ph.D.)  
Xian-Ping Lu, Ph.D., Chief Executive Officer & Chief Scientific Officer, Chipscreen Biosciences  
Shawn Qian, Ph.D., Co-Founder, Chief Executive Officer & President, NeuPharma  
Xiaodong Yang, M.D., Ph.D., President and CEO, Apexigen  
Dan Zhang, M.D., Ph.D., Chairman & Chief Executive Officer, Fountain Medicine Development Ltd

5:20pm – 5:50pm  Claim Construction Before PTAB and the Courts  
Thomas L. Irving, J.D., Partner & Wen Li Ph.D., Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

5:50pm – 5:55pm  Introduction to Medicilon  
Cheni Kwok, Ph.D., CLP , Senior Consultant, Medicilon and Managing Partner, Linear Dreams

5:55pm – 6:00pm  Introduction to Pharmaron  
Connie Sun, Ph.D., Senior Vice President, Business and Corporate Development, Pharmaron

6:00pm – 6:45pm  Networking Session

6:45pm – 7:15pm  Dinner

7:15pm - 7:30pm  Burma, the Golden Land. A Photographic Journey in Support of Global Health  
Steven Adams, DVM, Ph.D., Executive Director, Portfolio & Operations for Oncology Research Worldwide R&D, Pfizer

Evening Session: US-China Cross-Border Healthcare Investment & Entrepreneurship  
Session Chair: Yan Wang, Ph.D.

7:30pm – 9:00pm  Panel Discussion: US-China Cross-Border Healthcare Investment & Entrepreneurship  
(Moderator: Alexis Ji Ph.D., MBA)  
Min Cui, Ph.D., Founding Partner & Managing Director, Decheng Capital  
Alexis Ji, Ph.D., MBA, Principal, WuXi Healthcare Ventures  
Shawn Lee, Ph.D., Vice-Chairman, Xinbang Pharmaceuticals; President & CEO, CPC Scientific Inc.  
Cheng Liu, Ph.D., Founder & Chief Executive Officer, Eureka Therapeutics  
Vincent Liu, Ph.D., Senior Consultant, Wanbang BioPharmaceutical, Shanghai Fosun Pharmaceutical (Group) Co. Ltd.  
Yuwen Liu, Founding Partner, Bohe Angel Fund  
James Zhao, M.D., Founding Partner, LYFE Capital  
Darren Ji, M.D., Ph.D., MBA, Vice President and Global Head of Roche Partnering, Asia and Emerging Markets  
Jennifer Hu, Ph.D., Venture Partner, Qiming Venture Partners

9:00pm  Conference Adjourned

* The official working language of the conference is English
Somewhere between Science and Humanity

Bio
Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments.

In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such as oncolytic viruses (BioVex, DNAtrix), cancer vaccines (Aduro), modified cytotoxic agents (Nucana) and novel targets for therapeutic intervention (CellCentric, K-Gen, Vigeo). Other investments cover the therapeutic areas of metabolic diseases (CVI), autoimmune diseases (Kezar), CNS disorders (Orthogonal, Synchroneuron, Cognao), and rare orphan diseases (Stealth, Apellis), as well as molecular diagnostics (ACD), drug delivery (Medtrum, Incarda) and medical devices (ViOptix, Kona, Excera).

Gerald is a member of the advisory boards of the International Society for Stem Cell Research, the New York Academy of Science, Cold Spring Harbor Conferences Asia, Johns Hopkins Nanjing Center, and Columbia University Center for Radiological Research. At Harvard University, he is a member of the Global Advisory Council, the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of Morningside College of Chinese University of Hong Kong.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University. In 2012, he was the commencement speaker of the Harvard T.H. Chan School of Public Health.
Abstract:
Having led two M & A transactions in the last 4 years, my presentation will look at some of the key factors that influence and ultimately bring about a successful transaction. I will use the two events as case studies and try and provide the audience an understanding of how some of the key decisions that were made help to bring about success. We will also look at some of the learnings from the case studies and these in turn should help the audience navigate their own issues. The presentation will try and provide, as near as possible, a template to a successful transaction.

Bio
Hari Kumar is a Pharmaceutical executive with over 25 years of experience in the industry.

In his time, Hari has overseen the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and gastric ulcer drug, Aciphex®. He was also involved in guiding cross functional teams at Roche for the Transplantation franchise which resulted in the growth of the products in the franchise to achieve billion dollar sales. In his role as lead in-licensing person for inflammation at Roche, he identified and partnered valuable products that have enhanced Roche’s portfolio. He was instrumental in partnerships with Isotechnika, Biotie, Biocryst and Actelion. Experience in almost all aspects of the pharmaceutical industry has given Hari a unique understanding on what makes a successful pharmaceutical business.

At Amira, Hari led the process that resulted in the acquisition by Bristol Myers Squibb in 2011. His second big acquisition came as CEO and Board member of Adheron Therapeutics, Inc which was bought by Roche. He has now led two acquisitions which have resulted in over a billion dollars in returns to investors.

Having trained as an immunologist at University College London where he completed his PhD under the supervision of Prof N A Mitchison, Hari completed a postdoctoral fellowship at Tufts New England Medical Center in Boston and another fellowship at the Marie Curie Cancer Research Centre in UK.
Abstract:
Vaccines are one of the oldest medical interventions and have had a huge impact on human health, but historically have been something of a backwater for the broader biopharmaceutical industry. What lessons might the vaccine industry have for the sector more broadly? And how does one small company, PaxVax, intend to compete and win in a mature industry structure?

Bio
Mr. Whitehead joined PaxVax in early 2013 and brings 20 years of experience in the vaccines and biopharmaceutical industries. He previously served as Vice President of Corporate Development for Paris–based Neovacs. Prior to that, he was Vice President of Corporate and Business Development for vaccine company, VaxGen. At VaxGen, he negotiated several important partnerships and led the company’s commercial strategy, resulting in the award of a nearly one billion dollar Project Bioshield Act contract. He also spent 10 years at Mercer Management Consulting, where he headed the San Francisco office and led marketing, strategy, and manufacturing projects for clients including the Global Alliance for Vaccines and Immunization (GAVI), UNICEF, and several private–sector pharmaceutical and biopharmaceutical companies. Mr. Whitehead has published extensively on the vaccine industry and related public policy matters and holds an A.B. from Oriel College, Oxford University, England.
Abstract:
Mr Robert Lou will provide a historical prospective of the formation and growth of Chinese life sciences parks, an overview on the distribution of life sciences parks throughout China as well as an analysis of the resources provided by the parks to address the needs of the life sciences industry. Mr Lou’s presentation will also discuss how life sciences parks can further improve their competitive advantages to tailor to the needs of the industry.

Bio
Robert Lou is the founder and managing director of Ningbo Kangtaibo Technology Development Co., Ltd, which is constructing and operating BioVillage, a life science park with 250,000 m³ building area in Ningbo Hangzhou Bay New Zone. In 2010, he founded Hangzhou Honor Investment, an investment company mainly focusing on early stage companies investment in life science field. Before that, he had been engaged in international containerized transportation for more than 10 years and tourism industry for more than 5 years.

Robert Lou got a bachelor degree majoring in Nuclear Engineering in 1987, and a master degree majoring in Enterprise Management in 1990 from Shanghai Jiaotong University.

Robert Lou is the early investor of Pharmaron.
Introduction to Ningbo Hangzhou Bay New Zone

Abstract:
Introduction to Ningbo Hangzhou Bay New Zone
Mr Hui Zhang will give an introduction to Ningbo Hangzhou Bay New Zone, highlighting the zone's key achievements.

Mr Hui Zhang is the Deputy Director of Ningbo Hangzhou Bay New Zone Investments and Partnership. Mr Zhang supports the Director and is responsible for two branches of industrial investment: First branch and Second Branch (International Investment Branch). Mr Zhang is responsible for promoting international business development for the sectors including automobile and parts; civil aviation, life sciences and wellness as well as biopharmaceuticals.
Abstract:
Located in Chengdu, China, Chengdu Kanghong Biotech Co is one of the 7 subsidiaries of the 20-year-old Chengdu Kanghong Pharmaceutical Group Co. It is a leading biopharmaceutical company in China, which specializes in the discovery, development, manufacture, and marketing of innovative biologics. Its first biologics, Conbercept, is a novel anti-VEGF (Vascular Endothelial Growth Factor) agent. This is a recombinant fusion protein, including the domain 2 of VEGF receptor (VEGFR)-1, domain 3 and 4 of VEGFR-2, plus human IgG Fc fragment. Conbercept has high VEGF binding affinity, is a 100% humanized protein, and can target multiple VEGF subtypes, including VEGF-A, VEGF-B and PIGF. After 5 clinical trials were successfully finished, Conbercept Ophthalmic Injection was approved to treat Neovascular Age-Related Macular Degeneration (wet AMD) by the CFDA in December, 2013, and launched in China market in March, 2014. Now other indications in ophthalmology, such as Choroidal Neovascularization Secondary to Pathological Myopia (pmCNV), Diabetic Macular Edema (DME), and Retinal Vein Occlusion(RVO) are under late-stage clinical development. Conbercept has demonstrated well-tolerated safety profile and superior efficacy, and has been well received in the Chinese market. Holding strong global IP protection, Chengdu Kanghong Biotech is actively pursuing expansion of Conbercept into global market. Meanwhile, Chengdu Kanghong Biotech has a strong pipeline in R&D including KH903 for the treatment of different tumors, and KH906 for the treatment of neovascularization corneal diseases.

Bio
Jinqun Yin, MBA is the VP of Chengdu Kanghong Pharmaceutical Group Co, Ltd and Head of Marketing, Sales, Medical Affairs, Government Affairs, and Enterprise Brand Communication. He is a graduate from Beijing International MBA at Peking University and has 15 years working experience in multinational pharmaceutical companies, starting in Johnson & Johnson as a medical representative through regional director in China.

In early 2008, joined Bayer Pharmaceuticals as the director of national antithrombotic business unit, led a team to successfully launch Bayer’s global strategic product Xarelto (Rivaroxaban ) in China and uplifted the classic Bayaspirin to the best in Chinese market. In 2011, led and implemented Bayer’s “Chinese Growth Strategy”, working as the director of emerging market development division. Established new mode of “integral promotion of all products” and expanded sales to 4th and 5th line cities in China. After Conbercept was launched in the market, it broke several records of marketing and sales in Chinese pharmaceutical industry. Due to its excellent profile of safety and efficacy in clinic and great contribution to the community in China, Conbercept was awarded one of the best innovative drugs of clinical value by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and the People Net in China. In the past 10 years, only 3 drugs were selected and awarded from all drugs which were launched in the past 10 years in China.
Abstract:
The concept of antibody immunotherapy for cancer originated in the laboratory of Dr. James Allison in a paper published in 1996. It took nearly 20 years to bring antibody drugs to patients and to change the treatment paradigm from chemotherapy to include immunotherapy. While anti-PD-1 and anti-PD-L1 antibodies are leading this revolution by promoting deep and durable responses in various cancers, much is yet to be done to ensure greater response rates and expand the repertoire of responsive malignancies. I will highlight the direction of the pharmaceutical industry to meet this challenge and note learnings from in vivo mouse tumor models. Focusing on antibody therapies, I will highlight new targets and therapies which may make cancer a more manageable disease with more options for patients.

Bio
I completed my graduate studies in the UCSF laboratory of Dr. William Rutter where I cloned and sequenced the Nerve Growth Factor cDNA. I also determined the mouse NGF genomic organization and studied proteolytic processing of the NGF precursor protein. I completed my post-doctoral research in the laboratory of Dr. Matija Peterlin, also at UCSF. Here I researched regulation of HIV LTR transcription focusing on the TAT transcriptional activator and its interaction with the TAR sequence at the 5’ end of HIV transcripts. Thereafter I joined the Vaccines group at Chiron, working with Michael Houghton on HCV and then with Jeffery Ulmer on DNA vaccination. In 2001 I left Chiron and joined Alan Korman at Medarex. Here we studied the anti-CTLA-4 antibody, ipilimumab. Later, with other colleagues, we developed the nivolumab anti-PD-1 antibody and several other fully human antibodies for oncology.
Abstract:
The bacterial CRISPR/Cas9 system offers an approach for RNA-guided genome manipulation in mammalian cells, useful for interrogating and profiling gene functions. We have developed a versatile non-mutagenic genome manipulation platform based on the nuclease-dead Cas9 (dCas9), named CRISPR interference (CRISPRi), which enables complex orthogonal and inducible transcriptional regulation. Using these orthogonally acting dCas9s, we show that the platform enables robust activation and repression of multiple endogenous genes in the genome. We demonstrate the system allows high-throughput whole-genome screening of gene function, and show its uses for modeling diseases such as cardiomyopathy using human induced pluripotent stem (iPS) cells and iPS-derived cardiomyocytes. We compare the use of CRISPRi and CRISPR for different purpose of gene manipulation, and highlight the interesting features comparing gene regulation to gene editing. Finally, we show the use of dCas9 for other genomic studies including capturing the dynamics of chromosome loci in living mammalian cells. The talk will highlight the development and use of CRISPR and dCas9 for non-editing based genome manipulation and its potential applications.

Bio
Dr. Lei (Stanley) Qi is an assistant professor in the Department of Bioengineering, and of Chemical and Systems Biology. He is also faculty fellow in the interdisciplinary Institute for Chemistry, Engineering, and Medicine for Human Health (ChEM-H). He obtained his Ph.D. in Bioengineering from UC Berkeley, and started his lab as Systems Biology Faculty Fellow at UCSF. He is interested in developing novel technologies for cancer and immunology disease research, and Systems and Synthetic Biology. He is one of the major pioneers in the CRISPR technology for targeted genome engineering in mammalian cells. Different from most developers of the CRISPR tools, he has developed a series of gene regulation and imaging technologies, including CRISPR interference (CRISPRi), CRISPR imaging, and high-throughput CRISPR screening. He also worked in the fields of Synthetic Biology, and developed methods to generate synthetic noncoding RNA regulators of transcription, translation, and as molecular sensor for chemicals and intracellular proteins.
**Abstract:**
A successful partnering is an art. It takes many components to build one. Solid science, differentiated benefits, trust, story, terms, creativity, right people and timing. All these great elements have to come together in a coherent way to date, to dance and to marry. On this topic Darren shares his experiences and perspectives from both sides as a corporate executive and as a past entrepreneur.

**Bio**
Dr. Darren Ji is currently Vice President and Global Head, Asia and Emerging Markets Partnering, Roche. Darren was previously President and CEO of NPBiosciences, a biotech company based in Singapore. Prior to that Darren founded and served as CEO of PharmaLegacy Laboratories, which is a Shanghai-based Contract Research Organization specializing in preclinical pharmacology services. Darren spent 11 years at the Procter & Gamble Company with progressive responsibilities in drug research and development, and as director of bioscience business development in East Asia.

Darren previously served as a Board Director, and Shanghai regional leader of the BayHelix Group, a global organization of Chinese business leaders in life sciences. Darren obtained his medical degree from China Medical University, China; a PhD from the University of Sheffield, UK; and an MBA from University of Chicago, USA.
Abstract:
Morrison & Foerster Corporate Partner Chuck Comey will overview recent market data on China-US life sciences strategic / VC investment and highlight interesting issues from a two recent cases, the first a corporate VC investment / strategic alliance, the second an acquisition, involving Chinese companies partnering or acquiring U.S. life sciences companies.

Bio
Charles Comey is an M&A and corporate finance partner in the firm’s Palo Alto office. Mr. Comey’s practice experience includes working on the ground in China and Japan for 16 years. He advises clients on mergers and acquisitions, venture capital and private equity financings, and joint ventures and strategic alliances in the technology, consumer and life sciences sectors.

Beginning in 1994, Mr. Comey was seconded by Morrison & Foerster to the legal department of a major Japanese trading company, and thereafter was resident for nine years in Morrison & Foerster’s Tokyo office, where he specialized in cross-border mergers and acquisitions and strategic alliances. Before relocating to Silicon Valley in July 2010, Mr. Comey opened and served as managing partner of the firm’s Shanghai office from 2003 – 2010.

Mr. Comey is admitted to practice in California and is a member of the California and American bar associations. He speaks and reads Mandarin

Mr. Comey is recommended as a leading lawyer by Chambers Global 2015 (PE expert based abroad – China focus, PE foreign expert – US focus), Chambers USA 2014 and 2015 (California Corporate/M&A: Deals in Asia), Legal 500 Asia Pacific 2015 (Corporate and M&A – Foreign Firms), Legal 500 US 2013, Chambers Asia 2011, IFLR1000 2012, PLC Which lawyer? 2010 and Euromoney’s Expert Guides.

Key Trends and Case Studies: U.S. – China Cross-Border Life Sciences Investment and Strategic Cooperation
Abstract:
Tom Irving and Wen Li will discuss how to use fundamentally sound principles to prepare and prosecute a U.S. biopharmaceutical patent application to enhance the chances of obtaining a desired claim construction that is appropriate to business objectives and with a view to preempting potential issues in district court litigation and PTAB proceedings. With the rising tension between the district courts and PTAB standards in claim construction presenting important claim construction developments for practitioners right now, the take-home message remains to lay the groundwork in the specification (the “single best guide” to the meaning of a claim term) for the desired claim construction(s) to withstand both district court and PTAB challenges and yet also cover the reasonably foreseeable competitive products.
Bio of Thomas L. Irving
Tom Irving has more than 40 years of experience in the field of intellectual property law. His practice includes America Invents Act (AIA) post-grant proceedings, due diligence, counseling, patent prosecution, and reissue and reexamination. He counsels clients on a wide range of mainly pharmaceutical matters, including pre-litigation, Orange Book listings of patents covering FDA approved drugs, infringement issues, enforceability and validity analysis, and litigation. A significant portion of Mr. Irving’s current practice is focused on AIA post-grant proceedings, including how to enhance the strength of patents in the pharmaceutical space to protect against post-grant challenges. He has served as lead counsel in numerous patent interferences, reissues, and reexaminations; as counsel in numerous AIA post-grant proceedings; and as an expert witness in patent litigation.

Mr. Irving has been involved in every facet of several U.S. district court litigations, thus enhancing his ability to render advice in due diligence, enforceability, infringement, validity, and patent prosecution areas. Mr. Irving has served for more than 25 years as principal teacher of the Patent Resources Group (PRG) Chemical Patent Practice course, a comprehensive U.S. chemical patent law course taught two times a year, and he coauthors the multi-volume treatise used in the course. In addition, Mr. Irving originated PRG’s Orange Book and Due Diligence courses, which help prepare patent owners, through effective application drafting and prosecution, to withstand the rigors of AIA’s inter partes review (IPR) and post-grant review (PGR). He presents analyses of U.S. Court of Appeals for the Federal Circuit patent decisions for many state bar association groups and has spoken at numerous national bar association meetings such as the American Intellectual Property Law Association (AIPLA), Intellectual Property Owners Association, and American Bar Association. Mr. Irving has lectured at many law schools in both the United States and China. He also has lectured at the Cold Spring Harbor National Laboratory graduate school, the Patent Office of the State Intellectual Property Office (SIPO) of the People’s Republic of China, and has presented nearly 50 Strafford Webinars on patent law topics, including a number that deal with AIA’s post-grant proceedings. Outside of the patent law field, he has been involved in public health and safety issues related to the preparation of Citizen Petitions before the FDA for pharmaceutical matters.

Bio of Wen Li
Wen Li focuses her practice on U.S. and international patent prosecution in the pharmaceutical and chemical areas. Her experience includes managing world-wide patent portfolios for important pharmaceutical companies. Her practice also includes patent litigation, due diligence investigations, patentability/infringement opinion drafting, and client counseling.

Dr. Li has an extensive scientific background and experience in pharmaceutical research. Before joining the firm, she worked for a number of years as a senior/principal medicinal chemist in a biopharmaceutical company where she gained experience in designing and synthesizing small molecule antagonists for GPCRs and Integrin receptors. Dr. Li was a named inventor in several patents in these fields. In addition to having an in-depth understanding of pharmaceutical chemistry, she also has a deep understanding of concepts concerning bioavailability, which include Cmax, AUC, and ADME. She applies her background by working with expert witnesses, particularly in areas involving XRPD, HPLC, and NMR.

Dr. Li’s research background includes synthesis of unnatural amino acids and macrocyclics, as well as the study of secondary structures of peptidomimetics. Dr. Li is also familiar with a wide range of chemistry principles, which include physical chemistry, peptide chemistry, polymer chemistry, and transition-metal catalysis chemistry.
Panel Discussion: BioPharmaceutical Development - China & Global Considerations

Bio
Dr. Shawn Qian is a Co-Founder, President & CEO at NeuPharma, a biopharmaceutical company dedicated to the research and development of innovative medicines for unmet medical needs. Before co-founding NeuPharma, Dr. Qian was an Associate Director of Medicinal Chemistry and Program Leader at Cytokinetics, where he was responsible for the medicinal chemistry efforts on the discovery of novel therapeutics for the treatment of cancer, asthma and cardiovascular diseases. Prior to joining Cytokinetics, Dr. Qian was a NSERC post-doctoral fellow at Harvard University. Dr. Qian received his Ph.D. in Organic Chemistry from University of Alberta, Canada in 2000, and B.Sc. in Chemistry from Nanjing University, China in 1993. He is an author of 42 papers and an inventor of over 50 patents.

Shawn Qian, Ph.D.
Co-Founder, Chief Executive Officer & President, NeuPharma

Bio
Dr. Xian-Ping Lu founded Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics, 15 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D (subsidiary of L'Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals.

Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University.

With over 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 80 peer-reviewed papers in prestigious journals including Nature and Science. He is the lead inventor of over 80 patented inventions in areas of small molecule therapeutics.

Xian-Ping Lu, Ph.D.
Chief Executive Officer & Chief Scientific Officer
Chipscreen Biosciences
Bio
Dr. Dan Zhang has more than 15 year of drug development experience. He is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with operations in South East Asia, China, Armenia and USA. With 400 employees, FMD runs phase I/II/III/IV operations with full support of regulatory affairs, data management and biostatistics, EDC and pharmacoconomics operations. FMD has 70 employees in Philadelphia of USA and have filed 15 NDAs in last 2 years and obtained approval for 10 NDA applications.

Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp., a member of Quintiles Executive Operation Committee, and was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc.

Over last the 15 years, Dr. Zhang has provided services for the government and academic institutions in China. He is a member of grant review committee for National Key Drug Development Fund jointly managed by the Ministry of Science & Technology (MOST) and the National Health and Family Planning Commission of China (NHFPC). He chaired the Bayhelix’ CFDA working committee and works with the agency on the development of technical guidelines. He was a member of the Overseas Expert Committee on New Drug R&D from MOST. He is the senior consultant to Chinese Academy of Medical Sciences and Peking Union Medical College. He was also a visiting professor at the Harbin Medical University of China, Nankai University and Science and Technology University of South China. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA), and a board of director of Bayhelix. He is the Secretary-General of the Association of Thousand Talents Program.

Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance.
**SPEAKERS**

**Bio**
Xiaodong Yang, M.D., Ph.D., is President and Chief Executive Officer at Apexigen. Xiaodong spent two plus decades in drug discovery and development in the industry, focusing on antibody and oligonucleotide therapeutics. Prior to joining Apexigen, he was Vice President of Research and Preclinical Development at Intradigm Corporation which was acquired by Silence Therapeutics. In this role, he was responsible for overseeing the progress of company’s discovery and preclinical development of RNAi-based therapeutics. Xiaodong began his career as a founding scientist at Abgenix (acquired by Amgen) where he was Senior Director and the head of the Oncology Therapeutic Program Team responsible for setting strategy and managing the company’s oncology portfolio. He played a key role in discovery, development and BLA approval for Vectibix®. He was also in charge of the company’s partnerships on a number of therapeutic antibody collaboration programs. Xiaodong received MD from Beijing Medical University and his PhD from University of Bern. He trained at Stanford University School of Medicine and Novartis.

**Introduction to Medicilon**
Medicilon offers fully integrated pharmaceutical services for the global scientific community. We focus on providing an exceptional client-centered experience and advancing the drug discovery process. Medicilon has been recognized as one of the top drug discovery contract research organizations (CRO) in China and is managed by a team of scientists with a wealth of experience in US-based pharmaceutical and biotechnology companies.

My talk will provide an executive overview of Medicilon’s integrated services across biology, chemistry and preclinical services which are designed to help clients developing their research and discovery programs from the initial idea stage to the IND filing phase.

**Bio**
Cheni Kwok, Ph.D., CLP is the Senior Consultant of Shanghai Medicilon and the Managing Partner of Linear Dreams LLC, a management consultancy and valuation software firm specialized on corporate strategy, business/corporate development, portfolio analysis and valuation services for the life science industry. She has a broad range of operational expertise and established over 100 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing.

As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and
forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera’s small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica®(ibrutinib)) to Pharmacyclics Inc.. Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now Glaxo SmithKline).

Dr. Kwok received a bachelor’s degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society. Dr. Kwok currently serves as the Chair of the American Cancer Society’s California Chinese Unit, President-Elect of the Chinese-American Biopharmaceutical Society (CABS) and Board of Directors of the Chinese Bioscience Association (CBA).

Introduction to Phamaron

Phamaron is a premier R&D service provider for the pharmaceutical industry. Phamaron’s mission is to provide the highest quality R&D services while helping our customers advance their projects in a timely and cost effective manner. Founded in 2003, Phamaron has invested in our people and our facilities, enabling us to provide high quality R&D service across a number of disciplines including chemistry, biology, DMPK, pharmacology, toxicology and chemical development. Phamaron has grown steadily to meet the needs of our customers. With over 3,000 employees and operations in China, U.S. and United Kingdom, Phamaron delivers superior scientific services while maintaining close communication with our customers. Our current clients include small and large pharmaceutical companies in North America, Europe, Japan and China.

Bio

Connie is Senior Vice President of Business & Corporate Development. She is responsible for cross functional business & corporate development, partnership alliance management, and program management.

Prior to joining Phamaron, she has 16-year drug discovery and development experiences (author of 35 publications and inventor of 47 patents) at Biotech/Pharma. She is an inventor of Sutent® currently marketed by Pfizer. Her previous employments include head of Chemistry at Poniard Pharmaceuticals, Sr. Director at AGY Therapeutics Inc., and Director of Chemistry at Pfizer (SUGEN).

Connie holds a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill, North Carolina. Her postdoc training was at Parke-Davis, Warner-Lambert (later Pfizer), Ann Arbor, MI.
Burma, the Golden Land. A Photographic Journey in Support of Global Health

Abstract:
“I was originally drawn to Myanmar to capture iconic photographic images of a culture largely unchanged for more than 50 years. During my first visit in early 2015, I was fortunate to identify a unique opportunity to impact the health of children in a country with one of the poorest health care systems in the world ( Ranked #190/190 by World Health Organization). Later that same year, I launched Project Kalay.” Steven Adams DVM, PhD.

The Naga Hlainggu monastery in Yangon, Myanmar cares for more than 1400 orphaned boys and girls. While these children can come from anywhere in Myanmar, a large percentage originates from areas plagued by armed conflict, smuggling, drug trade, and human trafficking. Since this orphanage is also a monastery, it relies exclusively on private donations for all of its support.

While the health care needs of the children at this orphanage are vast, Dr. Adams has focused the efforts of Project Kalay on the most fundamental and basic delivery of hygiene. Our primary goal is to provide hygiene and health education and a steady supply of hand soap in the underserved monastic orphanages in Myanmar. Our first orphanage is the Naga Hlainggu monastery in Yangon, but we hope to eventually extend our efforts to other similarly needy orphanages.

Hand washing with soap is a proven means of delivering highly cost-effective disease prevention. The global private-public organization “Partnership for Hand Washing” estimates an investment of US $3.35 in hand washing promotion is estimated to deliver the same amount of health benefit as a US$11 investment in latrine construction, or an investment of many thousands of US dollars in immunizations. Schools provide a critical learning environment for children as well as a vehicle to initiate long-term change in the community.

Bio
Steven Adams is Executive Director of Portfolio and Operations for Oncology Research at Pfizer Worldwide R&D. In addition to his career as a veterinarian and scientist, he is an avid traveller and photographer. He offers his photographic work for sale as fine art prints and donates all profit to support Project Kalay (see swadamsphoto.com). For further information on Project Kalay see www.projectkalay.org.
Panel Discussion: US-China Cross-Border Healthcare Investment & Entrepreneurship

**Bio**

Dr. Min Cui is the Founding Partner and Managing Director of Decheng Capital. Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm, and focused on evaluating investment opportunities as well as its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005, respectively. In these positions, he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of GenapSys, GeneWeave Biosciences (acquired by Roche for $425M), Ketai Medical, Shenzhen GeneMDx Biotechnology, Accuragen and Sinomed. His investment portfolio also includes Ion Torrent Systems (acquired by Life Technologies for $725M), GenturaDx (acquired by Luminex), China Biologic Products (NASDAQ: CBPO), Epizyme (NASDAQ: EPZM), and Sunesis (NASDAQ: SNSS). Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America. He received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University.

**Min Cui, Ph.D.**
Founding Partner & Managing Director
Decheng Capital

---

Alexis Yongmei Ji, Ph.D., MBA
Principal
WuXi Healthcare Ventures

**Bio**

Alexis Ji joined WuXi Healthcare Ventures as a principal in 2014. She brings 12 years of research, product development and investing experience in the biotechnology industry. At WuXi Ventures, she is responsible for evaluating and investing in early-stage companies in the US, focusing on opportunities in therapeutics, devices, diagnostics, and healthcare IT. Before joining WuXi, Alexis worked at ARCH Venture Partners on life science venture investment. Alexis started her career in senior scientist positions at Merck, Roche, and Life Technologies, with rich experience in drug discovery and development, molecular diagnostics, and genomics. Alexis holds a PhD in Molecular Genetics from Washington University in St. Louis and an MBA from University of Chicago Booth School of Business.
Bio
Dr. Shawn Lee serves as vice-Chairman of Xinbang Pharmaceutical (Stock# 002390). Xinbang is a Healthcare company operating in Pharmaceuticals, Hospitals, Biotech services and Medical devices. He founded Chinese Peptide Company (CPC Hangzhou) in 2001 and currently serves as its Chairman of the Board. It is the first peptide CRO out of China and premier peptide CRO/CMO in the world today. CPC's 210,000 sf cGMP facilities have passed many successful inspections, CFDA and US FDA. Among its several hundred clients are top twenty pharmaceutical companies, innovative biotech companies and renowned scientific institutions. Peptide drugs/devices CPC supported have gained approvals in China, Singapore and Europe. Many of CPC's IVD/POCT devices have 510K and clear waive status within FDA. He has substantial experience in entrepreneurship, corporate finance, technology transfer, licensing and business development. Dr. Lee also serves as CEO of CPC Scientific Inc, a Silicon Valley company he founded in 2005. He is actively supporting other startup companies as partner of SVC Angel, Haibang Venture.

Shawn Lee, Ph.D.
President and CEO
CPC Scientific Inc.

Bio
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a California company dedicated to development of innovative cancer immunotherapy. Dr. Liu worked at Chiron (now Novartis), where he championed development of first-in-class therapeutic antibody against CSF-1, a key immune regulator, for cancer metastasis treatment. He has multiple issued US and international patents and scientific publications, including in journals of Science and Nature, in the area of therapeutic antibody discovery and engineering. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

Cheng Liu, Ph.D.
Founder & Chief Executive Officer
Eureka Therapeutics
Bio

Dr. Liu joined Wanbang Biopharm, a Fosun Pharma subsidiary in 2015 to lead its US business development effort. Recently he closed a deal to license two small molecule drugs from Rockwell Medical in a transaction of total $39m for upfront plus milestone payments. Currently Dr. Liu is focused on helping Wanbang and Fosun Pharma to acquire more product and technology for the Chinese market. Dr. Liu worked in International Business Division of Fosun Pharma Group from 2009 to 2015. His work covers Fosun Pharma’s investment and M&A strategies in the North America region. Upon joining the company, Dr. Liu has made significant contribution to implanting Fosun Pharma’s international strategies. His achievements including helping making a $40m investment in an innovated healthcare service company in NJ, raising a $500 million private equity fund from oversea and setting up two JVs with large US and Canadian companies in China. Before joining Fosun Pharma, he served in several Chinese and US startup companies as well as a healthcare focused PE/VC fund.

Dr. Liu received his Ph.D. degree in Molecular Biology in Drexel University and MBA degree from University of Rochester.

Bio

Founding Partner of Bohe Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI, etc. Before she set up this angel fund, she was Executive Director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) and chairwoman & CEO for 9 years. When she was also Investment Committee Member for BioVENTURE and Board Director of Innovent, Admera, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech.

She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.

She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager until she joined Perrigo as first China Chief Representative in 2003.

Yuwen graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI, and is a licensed pharmacist.
Bio

James Zhao MBA M.D. is a Founding Partner at LYFE Capital and focuses on investment in pharmaceutical, medical device, diagnostic, and animal health at our Shanghai office. Prior to establishing LYFE Capital, James has more than ten years of experience in investment in China. His previous investments include Jingfeng (SZ:000908), Shanghai Hile(SHA:603718.SS), Changchun Changshen and etc.

After the establishment of LYFE Capital, James has helped a domestic dental company successfully license in an orthodontic technology from USA, as well as build up the partnership between the dental company and a Swiss based company in dental implant sector. In addition, James has helped another domestic company build up partnership with one San Francisco based company and get the 510K approved product license-in to China.

A wealth of project experience has been accumulated from his constant international engagements and Venture Capital /growth stage investment, and James also gained abundant knowledge in investment, operations, strategy, cross border business development, sales/marketing and executive placement. James received his Medical Degree from West China University of Medical Sciences, M.S. in Molecular Biology from Vrije University in Brussels, and M.B.A. from Washington University, St. Louis.

Bio

Dr. Jing-Shan Hu joined Qiming Venture Partners as a Venture Partner in March 2016 with the focus on investment in healthcare companies in the US. She brings extensive experience in partnering, licensing, business development, R&D and management from three multinational pharmaceutical companies & two US biotech companies. Before Qiming, she was at Bayer Healthcare Pharmaceuticals as VP and Head of (External) Innovation Center China, responsible for building partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director at Merck & Co (MSD), heading early stage partnering/licensing activities in Greater China for Worldwide Licensing & External Research on novel drug candidates and technologies. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics & VEGF-2 Project Leader. While working at biotech companies, she has been successful in partnering with various organizations, including biotech industry and academia such as Stanford University. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ.
Chinese-American Biopharmaceutical Society (CABS) K. Fong Special Award

Dr. Gerald Chan to be Honored with CABS K. Fong Special Award - Visionary in Life Sciences

Chinese-American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that Dr. Gerald Chan is the winner of its CABS K. Fong Special Award - Visionary in Life Sciences for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies. Dr. Gerald Chan will be presented with this special award and we are honored that Dr. Chan will also be speaking at the 2016 BioPacific Conference (18th Annual Meeting of CABS) on 7th May 2016 at the San Mateo Marriott San Francisco Airport, 1770 South Amplett Blvd., San Mateo, CA 94402.

Dr. Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments. In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such as oncolytic viruses (BioVex, DNAtrix), cancer vaccines (Aduro), modified cytotoxic agents (Nucana) and novel targets for therapeutic intervention (CellCentric, K-Gen, Vigeo). Investments in the infectious disease area include novel antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Other investments cover the therapeutic areas of metabolic diseases (CVI), autoimmune diseases (Kezar), CNS disorders (Orthogonal, Synchroneuron, Cognoa), and rare orphan diseases (Stealth, Apellis), as well as molecular diagnostics (ACD), drug delivery (Medtrum, Incardia) and medical devices (ViOptix, Kona, Excera). Gerald is a member of the advisory boards of the International Society for Stem Cell Research, the New York Academy of Science, Cold Spring Harbor Conferences Asia, Johns Hopkins Nanjing Center, and Columbia University Center for Radiological Research. At Harvard University, he is a member of the Global Advisory Council, the Dean's Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of Morningside College of Chinese University of Hong Kong.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University. In 2012, he was the commencement speaker of the Harvard T.H. Chan School of Public Health.

“CABS is very proud to honor Dr. Gerald Chan for his life-time contribution in the field of life sciences, his significant achievement towards nurturing a new generation of innovative life sciences companies and his generous support of life sciences education, including a transformative gift of $350M to the Harvard School of Public Health, the largest donation in the 380-year history of the university,” said Dr. Jiangwen Majeti, President of CABS. “We are very grateful to Dr. Ken Fong for his generous long-term support of this award as well as other activities at CABS throughout the year.”
About CABS K. Fong Award in Life Sciences:

CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life. Candidates must be nominated by an active member of CABS followed by review and approval of the Selection Committee. Selection criteria will be based on candidate’s accomplishments in life sciences and contribution to the life science community, including one or all of the following:

• Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or the research reagent/equipment markets.

• Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.

• Significant contribution to the general biomedical and the CABS community and to promoting international collaboration in life sciences.
About Dr. Kenneth Fong:

Dr. Kenneth Fong is currently the founder and chairman of Kenson Ventures, LLC, a company that specializes in crafting development strategy for early and mid-stage stage biotech companies. Under his leadership, companies that were acquired or went public between 2007 and 2012 are: SA Biosciences (to Qiagen), DHI (to Quidel), Fermenta (to ThermoFisher), Panomics (to Affymetrix), Epitomics (to Abcam), Bioform (IPO) and Optimer (IPO). Currently, he sits on the boards of 5 biotech companies, including two biopharmaceutical, one diagnostic and two research tool company. Prior to Kenson, Ken founded and served as CEO of Clontech Laboratories (1984-1999), which was acquired by Becton Dickinson in 1999. Clontech, a leader in the life science market, was also the largest of its kind founded by an Asian American (400 people, including 65 PhD scientists) during the early years of the biotech industry. Ken served as president of Society of Chinese Bioscientists in North America (~2,000 members, 2005-09) and President of the Bay Area AAMA (1987). He was a member of the Board of Trustees of California State University (2006-2013), Board of Associates at the Whitehead Biomedical Institute at MIT and a member of the Committee of 100 (US). Ken has many other philanthropic interests. He was one of the lead supporters for the San Jose Tech Museum, the Chinese Historical Society in San Francisco, the Bioengineering Auditorium at UC San Diego and the Indiana University graduate Seminar Programs. He has provided Translational Science Awards through an endowed fund to the San Francisco State University. In addition, he has provided a number of scholarships to Peking University and the CSU students (Kenneth Fong–Hearst endowed Scholarships). In 2006, he was also involved in establishing the Fong Optometry and Medical Library at UC Berkeley and more recently an endowed professorship to Stanford University.

Currently Ken spends a good amount of time cultivating and advising a number of entrepreneurs (40-55 years old group) to grow their biotech companies.

Past recipients of CABS K. Fong Awards include:

2015: Dr. Irving Weissman of Stanford University for his pioneering research in stem cell research.

2014: Dr. Ge Li of Wuxi Apptec for creating and shaping the CRO business model in China and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and lopinavir.

2013: Dr. Peter Hirth of Plexxicon & Sugen for his pivotal role in advancing 4 successful drugs to the market and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.
CABS Activities
2015 – 2016
CABS Investor Forum 2016

January, 13th, 2016, San Francisco, CA

• J.P. Morgan Healthcare Conference is held in San Francisco in January every year, and we saw a tripling in the number of attendees from China in 2015.
• CABS serving as a bridge for the life sciences communities across the Pacific was uniquely positioned to host an investment forum at the same time.
• Our inaugural CABS Investor Forum organized in collaboration with ChinaBio and Morrison & Foerster discussed China-focused early-stage investments from the perspective of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs.
• Our forum featured five esteemed panelists from a broad spectrum of interest groups and moderated by Greg Scott, Founder, ChinaBio® Group:
  • Dr Nisa Leung, Managing Partner, Qiming Venture
  • Dr Masood Tayebi, Investor, Bridgewest Business Group
  • Dr Mike Liu, Head Global BD, Hengrui Pharma
  • Dr Wei Zheng, Co-founder, Suzhou Connect
  • Dr Janet Xiao, Partner, Morrison & Foerster
• More than 120 people attended the event. The in depth discussion, broad range of information shared, and energizing panelists provided CABS a successful basis for many future CABS Investor Forums to come.
Naturejobs Career Expo-San Francisco

April 27, 2016; San Francisco, CA

- Naturejobs Career Expo is a global career fair and conference for the science community across the UK, US, and Germany.
- San Francisco hosted the first Naturejobs Career Expo in 2016.
- Acting as an ambassador, CABS endorsed and actively promoted the Naturejobs Career Expo to scientists in our community.
- Over 20 exhibitors including Genentech, Merck, Fred Hutchinson Cancer Research Center were present.

- The conference and workshop sessions aimed to provide delegates with practical advice and inspiration to help achieve their career goals. The topics covered career in academia, career in industry, science communication, etc.
- This free one-day event also offered the attendees a chance to benefit from one-to-one resume checking; network with leading scientific institutions; learn how to enhance your employability; and maximize the career prospects.
BioSciKin (BSK)  
International Start-Up  
Competition for Life Sciences  
Companies San Francisco Bay Area Preliminary

April 7, 2016; Stanford University

- CABS was the lead organizer for the San Francisco preliminary, in collaboration with the Association of Chinese Students and Scholars at Stanford (ACSSS) and the California Life Sciences Institute (CLSI)
- We are proud for contributing to the success of the San Francisco Bay Area Preliminary, which was one of the largest US-China Life Sciences business plan competitions to date.
- BSK, a China-based open investment and incubation platform, in collaboration with Simcere Pharmaceutical Group and global venture capital firms were the sponsors for this international competition.
- The preliminaries of this competition were held in 8 cities, including San Francisco Bay Area and Boston and over 150 business plans from US companies were received.
- 70 applications were submitted for the preliminary at San Francisco Bay Area and 10 applicants were selected to present at the preliminary held on April 7 at Stanford University.
- This event was over-subscribed with over 150 people attending.
- The winner of the San Francisco Bay Area Preliminary was Fibralign Corporation, a South San Francisco based company, and was awarded $30,000 in non-dilutive funding. The runner-up was Denovo, a San Diego-based company. Both companies received a paid round-trip to Shanghai to participate in the final competition.
- CABS played a pivotal role in soliciting business plans, event promotion as well as on-site management of the San Francisco Bay Area Preliminary.
The CABS Science Technology Committee fosters scientific exchanges in the life science industry. Each year, the committee organizes a series of seminars to discuss the current trends and cutting edge technologies in life sciences, often focusing on a specific approach or technology throughout the year. Members of CABS not only benefit through the seminars but also have the opportunity to interact directly with the speakers who are usually veterans, well-known scholars, or entrepreneurs. In addition, the seminar series also provide members the opportunity to connect with other professionals with diverse areas of specialization, which could lead to unexpected insights. Detailed information for these and other events can be viewed at the CABS homepage (www.cabsweb.org).

2016 Upcoming Events

**Organ therapies and stem cell:** June 2016

**Drug development:** September 2016

**Omnics and big data:** October 2016

Past Events

**New Frontiers in Peripheral Monitoring**

September, 2015, Burlingame, CA

Liquid biopsies have now emerged as promising tools that are safer and cheaper than traditional tissue biopsies to survey health and disease state. For the first time, we are now able to obtain a wealth of information from blood and urine derived circulating DNA fragments that could revolutionize research and patient care. This workshop was led by founders and leaders of companies which have pioneered the frontiers of peripheral monitoring. We discussed the science and applications behind these novel technologies as well as the trials and tribulations of building a life science start-up.

**Event Speakers**

Christine Fu, Scientist, Fluxion Biosciences
Paul Tang, CTO, AccuraGen
Mojgan Haddad, Sr. Director, Bioinformatics and Analytics, Health Tell
John Waldeisen, Co-founder and CEO, DiAssess
Nikolay Sergeev, R & D leader, Natera

**Perspective in Single Cell Genomics—by Professor Stephen Quake**

February, 2016, Palo Alto, CA

This event was a collaboration between CABS and CLIPSS (Chinese Life-science Postdocs and Students At Stanford). In this workshop, Prof. Quake shared his perspectives on the emerging single-cell genomics. Advances in whole-genome and whole-transcriptome amplification have permitted the sequencing of the minute amounts of DNA and RNA present in a single cell. Single-cell approaches stand poised to revolutionize our capacity to understand the scale of genomic, epigenomic, and transcriptomic diversity that occurs during the lifetime of an individual organism. Single-cell techniques, ranging from flow cytometry and microfluidics to PCR and sequencing, are used to understand the cellular composition of complex tissues, find new microbial species, and perform genome-wide haplotyping.
Recent innovations in drug discovery
April 23, 2014, Burlingame, CA

Speakers in this workshop described elegant innovations in chemistry, which has opened new avenues in drug discovery. In particular, Dr. YK Zhang presented benzoxaborole chemistry in the search for antimalarial agents; benzoxaborole structure has not been widely used in drug discovery previously. Dr. Henry Johnson presented discovery efforts towards immunoproteasome, which recently has become exciting targets with the approval of bortezomib and carfilzomib as anticancer treatments. Lastly, Dr. Leping Li presented innovations in discovering new chemical space for generating successful IND candidates targeting hepatitis C virus (HCV) non-structural 5A (NS5A) protein.

Event Speakers
Dr. YK Zhang, Discovery of Benzoxaborole Antimalarial Agents, Research Leader of Anacor
Dr. Henry Johnson, Targeting the Immunoproteasome, Principal Scientist of Kezar Biotheapeutics
Dr. Leping Li, Expanding the HCV Infection Treatment Options through Chemistry, VP of Assembly Biosciences

Business & Career Development

2015 – 2016 Co-Chairs
Jessica Sun, Ph.D. and Alex J. Zhang, Ph.D.

2014 – 2015 Co-Chairs
Cheni Kwok, Ph.D., CLP and Sean Xiang Wu, Ph.D.

Our mission:
• To serve the business and career development needs of our members and the San Francisco Bay Area life sciences community
• To provide our members with interactive, informative platforms and networks to launch, to transition, or to advance their careers in the life sciences industry
• To enable our sponsors to effectively recruit talent, management team, and innovative projects

Upcoming Events
Entrepreneur Club (E-Club) will continue provide a network among existing and future entrepreneurs through workshops and casual lunch meetings.

BCD will organize workshops on interdisciplinary collaboration, to foster the collaboration between biosciences and technology fields.

BCD will co-organize job fairs and career development workshops to provide job seekers a way to explore career opportunities and to be better informed about the job market.

Past Events
CABS E-Club Event - Modern Seafarers: Navigating Life Sciences Investments and Entrepreneurships between US and the Far East
2015-06-10 , Palo Alto, CA

The life sciences sector reached new heights in performance in the IPO market as well as M&A in 2014. Global life sciences M&A deal value and volume surged to record high since 2000. What are the opportunities and challenges for entrepreneurs who wish to venture to the Far East? What are the investors looking for in funding new companies that operate on both sides of the Pacific Ocean? When will the trade winds change and what can we do as entrepreneurs and investors to catch them? Our modern seafarers will share their expertise and guide our entrepreneurs to navigating the Orient.

Modern Seafarers:
Anula Jayasuriya, MD., Ph.D., M.B.A., Co-founder of Evolvence India Life Sciences Fund
Cheng Liu, Ph.D., Founder & CEO, Eureka Therapeutics
Jonathan Norris, JD, Managing Director, Healthcare Practice, Silicon Valley Bank
Mohan Uttarwar, Co-Founder & CEO, IINx LifeCare, Inc.
Jimmy Wei, Ph.D., M.B.A., Venture Partner, KPCB, China
Moderators:
Glen Sato, JD, M.B.A., Partner, Cooley
Cheni Kwok, Ph.D., CLP, Managing Partner, Linear Dream

Co-hosted CABS Investor Forum 2016
January 13, 2016, San Francisco, CA

Biotech innovation goes hand-in-hand with investment. As the demand for novel products reaches a new height on both sides of the Pacific Ocean, we would like to invite you to participate in our first CABS Investor Forum featuring panelists from a broad spectrum of investment groups. We will discuss China-focused early-stage investments from the perspective of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs.

Panelist
Nisa Leung, Managing Partner, Qiming Venture
Masood Tayebi, Investor, Bridgewest Business Group
Mike Liu, Head Global BD, Hengrui Pharma
Wei Zheng, Co-founder, Suzhou Connect
Janet Xiao, Partner, Morrison & Foerster
Greg Scott, Founder, ChinaBio® Group (Moderator)

Career Advisory Network (CAN) Program
In keeping with its mission of engendering professional interaction and development within the biotech/pharma industry, the Chinese-American BioPharmaceutical Society (CABS) is offering a free mentoring program, Career Advisory Network (CAN), to help advance career goals of its active members.

CAN is a six-month program with 1:1 mentoring meetings and group network sessions. We have lined up an exceptional group of mentors with diverse expertise and experiences encompassing pharmaceutical R&D, biotechnology development, project management, business development, patent law, management consulting, venture capital and entrepreneurs. Once matched, mentees will meet with their mentor monthly to discuss specific career-building topics. As part of the process, participants will create a personal strategic plan for identifying ways to achieve career goals. CAN program has been successfully held for the past six years and received many positive feedbacks. It is an excellent opportunity to interact and network with a diverse group of people in academia and industry in a supportive and informal setting. 2016 CAN program continues to provide our members an interactive relationship with mentors discussing personalized career issues such as work life balance, transition alternative career path, entrepreneurship in US and China, workplace interpersonal skills and managerial skills.

2015 Mentor-Mentee Programs: Brunch Mix
September and October, 2015; Bay Area, CA

2015 CAN Program Graduation & Panel Discussion: Management and Leadership in Industry
November 14, 2015, Burlingame, CA

Congratulations to CAN Program Class of 2015! The biotech and pharmaceutical companies are operating in an era of transformation. Soft skills and the ability to work across disciplines have become prerequisite for career advancement. The technically skilled professionals must develop more management and business skills to capture these opportunities. Three successful biotech professionals shared their experience on leadership, communication, collaboration skills, time-, self-, project-management; and answer questions about career development.

Panelist
Shichang Miao, Ph.D., Senior Director, ChemoCentryx Inc
Kedan Lin, Ph.D. Senior Scientist and Therapeutic Area Leader, Genentech
Wentao Zhang, Ph. D., Founder of Quintara Discovery
International Collaboration

2015 – 2016 Co-Chairs
Yan Wang, Ph.D. and Wei Zhang, Ph.D.

2014 – 2015 Co-Chairs
Yan Wang, Ph.D. and Zhenhai Shen, Ph.D., M.B.A.

The CABS International Collaboration Committee (ICC) strives to promote international collaborations with various life sciences organizations and serves as a bridge that connects our members to life sciences communities in the Pacific Rim countries. In October 2015 we arranged our annual CABS entrepreneur delegation trip to China. From May 2015 to April 2016, we hosted multiple Bay Area events to facilitate networking and partnership opportunities including CABS Investor Forum and BioSciKin Contest for Life Science Start-ups.

Planned Events
We will host a partnering event at the day of BioPacific Conference and the day after for conference sponsors including China Science Parks and pharmaceutical companies to interact with CABS members for talent recruitment and project collaboration.

We will organize 2016 CABS member China trip in fall to introduce CABS members and their projects to the Science Parks, pharmaceutical companies and investment firms in China to seek project collaboration and job positions. We will continue to host various events to facilitate the networking and partnership opportunities, and promote international collaborations in the Pacific Rim countries.

Past Events

2015 CABS Delegation to Cities and Science Parks in China
October 7 to October 14, 2015

Dr. Yan Wang, Co-chair of 2015-2016 ICC, in collaboration with our executive committee, organized a delegation of CABS life sciences entrepreneurs to attend the “Entrepreneur Ningbo Trip” event and to visit science parks and life sciences companies in Ningbo and Hangzhou. The key objectives of this delegation were:

• To promote international life sciences collaborations between US and China

2015 CABS Delegation to China, meeting with BioClub and Zibo National High-Tech Industrial Development Zone at BioClub in Hangzhou
To enable our entrepreneurial members to evaluate opportunities to establish or to expand their operations in China; to enable CABS members to be able to find suitable job position in China pharmaceutical company

To gain insight from successful Chinese-based life sciences companies

To establish new CABS strategic collaborations with science parks and local governments in China

To raise awareness of CABS as a major Chinese-American life sciences professional organization

To provide a platform to share the latest trends of research and development in US with Chinese life sciences companies/organizations and to facilitate the recruitment of US life sciences talents, entrepreneurs and professionals to China

Discussion about Drug Discovery and Development Opportunities in China
May 10, 2015; Silicon Valley, CA

We hosted an informal but in-depth discussions with Dr. Jimmy Zhang, VP of Transactions at Johnson & Johnson Innovation. Dr. Zhang talked about drug discovery and development opportunities in China, as well as how to take advantage of the opportunities and participate in the process. Audiences are very interested in the topic and had a great discussion.

Introduction of CITIC Private Equity Funds Management Co., Ltd.
中信产业基金投资座谈会
June 17, 2015; Silicon Valley, CA

The CITIC delegation visited the Bay Area to seek suitable biotech companies and projects to fund and collaborate. Several CABS members presented their business plans at the meeting and got feedback. Meanwhile, the audiences had the opportunity to learn about the business environment in China introduced by CITIC.

Networking with Qilu Pharmaceutical
齐鲁制药对接洽谈会
September 4, 2015; Silicon Valley, CA

Senior executives of Qilu Pharmaceutical visited the Bay Area to look for talents to join Qilu in Jinan, Shandong province, and therapeutic project and platform for collaboration in the areas of biologics drug discovery and process development, small molecule formulation development, and innovative or me-better target drugs. CABS members are enthusiastic about the opportunities. The meeting included several presentations of CABS members’ projects as well as the introduction of the need from Qilu Pharmaceutical.
Real-time Video Meeting of BioClub Medical Device Conference
November 11, 2015; Silicon Valley, CA

BioClub hosted a medical device conference in Hangzhou where there were over 1000 attendees including executives, investors and entrepreneurs. In order to promote the communication and for CABS members to get familiar with the advancement in medical device area in China, we set up a video meeting in Silicon Valley to watch the conference in real-time. Afterwards, we discussed about innovation and entrepreneurship. People are very enthusiastic about sharing ideas and visions.

Tianjin Asymchem Company Recruitment Event
December 15, 2015; Berkeley, CA

We organized a talent recruitment event for Asymchem Laboratories Inc. in Tianjin, one of the world's leading contract manufacturing organizations providing the pharmaceutical industry with APIs and API intermediates. At the recruitment event at Berkeley, there were company introduction, questions and answers, and one-on-one interviews. People show interest to go back to China to work. It was also a great opportunity for people to get to be familiar with the working environment in China.

CABS Investor Forum 2016
January 13, 2016; San Francisco, CA

The president of CABS Jiangwen Majeti led ICC and BCD committee to organize the first investor forum of CABS. The forum was held in conjunction with JP Morgan Healthcare Investment Conference in 2016. The forum discussed China-focused early-stage investments from the perspective of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs. More than 150 people attended this forum. We invited featuring panelists from a broad spectrum of biotech-focused investment groups. They are: Nisa Leung, Managing Partner, Qiming Venture; Masood Tayebi, Investor, Bridgewater Business Group; Mike Liu, Head Global BD, Hengrui Pharma; Wei Zheng, Co-founder, Suzhou Connect; Janet Xiao, Partner, Morrison & Foerster; Greg Scott, Founder, ChinaBio® Group (Moderator)

Talent recruiting and project collaboration event with Chia Tai Tianqing Pharmaceutical Group
正大天晴药业集团推介会
February 28, 2016; Silicon Valley, CA

CABS helped Chia Tai Tianqing Pharmaceutical Group (CTTQ) to organize a talent recruiting and project collaboration event. Dr. Tong Xu, Chief Representative – North America, introduced the company. Dr. Ling Yang, Vice President of Project Management, shared the vision on project collaboration. Mr. Jie Zhang, Vice President, presented the key positions they are recruiting. Afterwards, there were small group meetings on project presentation and job interview. CABS members were enthusiastic about these opportunities. CTTQ is the leading pharmaceutical company with integrated R & D, manufacturing, distribution, marketing, and sales in China with 7500 employees currently. It is the market leader in drugs treating liver diseases in China since mid-1990.

BioSciKin Competition for Life Sciences Start-Ups
April 7, 2016; Silicon Valley, CA

Dr. Yan Wang, Co-chair of 2015-2016 ICC, led the extensive efforts to organize 2016 BioSciKin (BSK) Life Science Start-ups Contest in San Francisco Bay Area. This contest, mainly sponsored by BSK and Simcere Pharmaceutical Group, has six preliminaries in China and two in the US including San Francisco and Boston. This is the first time that China pharma and venture host such an event across China and the US in the life science space. BSK received over 150 applications from San Francisco and Boston start-ups, with over 70 for the Bay Area competition. Among the 70 start-ups, 10 were selected to present on the stage on April 7 at Stanford University. The top two winners were invited to the final contest in June in Shanghai. The first place winner, South San Francisco-based Fibralign Corporation, was awarded $30,000 prize and the second place winner, San Diego-based Denovo Biopharma, received a free round-trip to Shanghai for the final. Over 150 attendees witnessed the great success of the event.

In addition to the roadshow of the start-ups, Dr. Lin Wu, Vice President of Development for the Sequencing Business Unit of Roche Diagnostics, gave the keynote address on non-invasive liquid biopsy for cancer patients. The event also included remarks from Dr. Penghui Xu, Science Consul from Consulate General of the People's Republic of China in San Francisco, and Dr. Cheni Kwok, President-elect of CABS. The contest was organized by CABS, the Association of Chinese Students and Scholars at Stanford (ACSSS) and the California Life Sciences Institute (CLSI).
Social Life

2015 – 2016 Co-Chairs
Sihong Zhou, and Ken Zhang, Ph.D.
2014 – 2015 Co-Chairs
Bo Lian, Ph.D. and Jian Zhang, Ph.D.

The Social Life Committee (SLC) Statement

The Social Life Committee (SLC) is dedicated to serving our members with high quality indoor and outdoor activities. Within the CABS community, SLC intends to provide the opportunity to make connection, build relationship and enhance the interaction; to enrich and improve life quality by sharing knowledge, organizing fun events, and co-creating memorable experience.

The key objectives of CABS Social Life Committee are:
To serve our CABS members through hosting seminar & talks, and organizing social activities.
To provide networking and social interaction platform for CABS family.
To create opportunity for friendship and professional development.
To promote healthy and positive life style for our CABS community.

Coming Events:
• Group hiking and outdoor recreational activities
• Taste of the American culture
• Financial management and asset protection related seminars
• CABS Summer BBQ 2016
• Seminar about family relationship and health issues
• Green card and college application

Past Events

Annual Summer BBQ Networking Picnic
August 8, 2015, Foster City, CA

Over 250 CABS members, families and friends attended this well-organized party. In addition to the delicious food, people also enjoyed mingling with friends, playing sports and lots of other activities. We thank the participants for the support; we congratulate those on winning the lucky draws; we once again thank our volunteers for the tremendous help. And we also look forward to more and more people participating in our future events and activities!

2016 CABS Chinese New Year Party
January 31st, 2016, Foster City, CA

Happy Chinese New Year!!! CABS kicked off the Year of the Monkey with exciting CABS traditional New Year Festivities! More than 200 attendees, including volunteers and performers, were present.

Activities included singing and dancing, Beijing opera, other live musical entertainment, spring festival couplets and conundrum, and much more! Audience enjoyed the high quality of music and dancing performance. There were games for children and lucky draws for everybody! And the top lucky raffle winner went home with a new Apple iPad!!! People reconnected with old friends and made new ones while having fun celebrating Chinese New Year 2016 together!
Heart attack remains a leading cause of death in US and worldwide. Heart attack can result in critical reduction of blood and oxygen supply to heart for an extended period, which can cause irreversible heart muscle damage or death. It is important to control or eliminate the risk factors of heart attack. Also, it is critical to recognize the symptoms of a possible heart attack and take the appropriate action.

At the seminar, audience gained a better understanding of this disease, which is your first step to fully embracing self-care. The speaker, Dr. Lin, also introduced some tips to help develop an effective self-care plan.

*Co-hosted with Silicon Valley Sichuan University Alumni Association (SVSUAA)
宁波杭州湾新区位于宁波市北部，杭州湾跨海大桥南岸，是浙江省15个产业集聚区之一，陆域面积353平方公里，海域面积350平方公里。区内设有国家级经济技术开发区和国家级出口加工区。

新区已初步形成了产业、新城、湿地休闲三大功能板块，制造业区块已建成面积达50平方公里，累计落户工业企业项目435个；27平方公里商务新城建设快速推进，大型城市综合体、五星级酒店、高等院校、高等级医院及一批功能性项目相继建成，到2020年将建成能够容纳30万新居民入住的新城；湿地休闲区规划总面积63.5平方公里，目前4.3平方公里核心区域已建成并晋升为国家级湿地公园，湿地鸟类达220多种。

目前新区累计落户工业企业项目435个，投资企业331家，集聚了德国大众、德国博世、美国伟世通、荷兰联合利华等13家世界500强企业投资项目19个，汽车及关键零部件、电子电气、生命健康、高性能新材料、装备制造等一批新兴产业集聚发展并初具规模。

新区将倾力打造宁波杭州湾国际化滨海名城，着力构建先进制造集聚区、科技创新试验区、健康休闲生态区、产城人融合示范区，成为宁波北翼国际化开放门户和制造业创新中心。

支持政策

研发孵化：对孵化创业场所三年内给予不超过1500平方米的全额租金补助。
科技创新：对国家和宁波市认定的高新技术企业、科技型企业等给予减税、补助和奖励。
人才政策：享受享受宁波实际安家补助政策的基础上，给予20-80万的人才给予购房补贴。

宁波3315：宁波市财政对入选宁波3315项目的团队给予500-2000万人民币的人才和科研经费资助，新区给予一定比例的配套。

敬请联系：
许爱华（Bella）82989578@qq.com 139-5822-1932
郭 阳（Alex）448528649@qq.com 183-6842-9745
JOIN US NOW!

Science Park

BioVillage covers 16.7 hectares land area in total, in which 250,000㎡ of buildings with various functions will be constructed including incubator, office buildings, state-of-the-art GMP pilot laboratory, cutting-edge test & analysis platform and SPF experimental animal platform, etc. The goal is to create a science park with garden style. It is an internationalized way. The construction phase-I will be completed by the first half of year 2017.

Laboratory

The leading CRO Pharmaron, as the partner of BioVillage, will specially provide preferential package prices to those companies entering in BioVillage. You will be offered most professional, internationalized, first-class outsourcing service seamlessly, which undoubtedly save your cost and time dramatically.

Team

Simultaneously you will be offered one-stop service. Our specially assigned Service Executive helps with any problems you may meet, e.g. company registration, bank account opening, laboratory decoration, recruitment and training, government relationship and fund application, financing matters, and patent application, etc. What you have to do is to focus on your project development.

Guarantee

A good solution for any fund needs is schemed out: a professional VC specializing in investment in early-stage companies (those in the park only) will be established very soon. Please don’t worry! You will still hold the controlling stake of post-investment.
The Advantages of BioVillage

Geographical Advantage

Ningbo Hangzhou Bay New Zone, located on the southern bank of Hangzhou Bay Bridge, and being adjacent to 4 main central cities: Shanghai, Ningbo, Hangzhou and Suzhou, is becoming a bright star in China's Yangtze River Delta Region, where there are biggest amount of multinational bio-pharmaceutical enterprises stationed in. A cluster of life science parks gathering together in the region are creating a huge competitiveness over others in the field of life science. Ningbo Hangzhou Bay New Zone is well positioned to assure the industry's overspill in the region.

Entrepreneurship Environment

Ningbo municipal government office released the document <Guiding Opinions on Promoting the Innovation and Development of Life and Health Industry (2016～2020)> in last October, proposing for a specific management office to organize and coordinate the life science industry's development in the city. Increasing financial support could be anticipated to lead the gathering of the life and health industry in Ningbo. In 2015, Ningbo municipal government released 'New Talent Policies' intending to create "a paradise for brightest minds". The document proposed that the city would further increase 500 million Yuan of talent fund in the coming 5 years.

Outsourcing Services

BioVillage has already built seamless cooperative ties with Pharmaron, a leading CRO, in order to build up an integrative R&D platform from drug discovery to IND application. The platform covers small molecule synthesis, medchem, analytical chemistry, DMPK, bioanalysis, toxicology, CMC, and etc. Our goal is to provide with every aspect of helps you may need.

Administrative Services

The government of Ningbo Hangzhou Bay New Zone has created a perfect service-oriented environment with high efficiency and normative. BioVillage will also help with company registration, bank account opening, laboratory decoration, recruitment & training, government relationship & fund application, financing matters and patent application, etc.

Financial Support

BioVillage will establish "bio-pharmaceutical industry development fund". Together with other cooperative funds, the fund will invest in those companies in need for BioVillage's clients only. Government incentives: the "3315 Project" of Ningbo and "5 First Class Talent Project" of Ningbo Hangzhou Bay New Zone would offer financial support for innovative teams and professionals so as to attract more and more innovative talents rapidly.

Associated Industries

Package materials, moulds and equipments on phases of production and the sales link are available in the local Zhejiang Province — abundant with API and pharmaceutical intermediates supply.

Cost Saving

Low housing & living costs ease entrepreneurial pressure and give your employees quality life.

Land Supply

The precious industrial land supply can meet your demands for further business expansion.

Contact:

Dr. 陈 阳 Sarah  
sarahren@biovillage-nb.com  
+86 13521892827

Mr. 徐 若 Vincent  
vicent10@biovillage-nb.com  
+86 13884922020

Ms. 葛 艾 Ella  
ellia@biovillage-nb.com  
+86 13857888089

Ningbo Kangtunbo Technology Development Co., Ltd  
Add: Room 1106, Technology Innovation Center, No.1188 Binhai 2nd Rd, Hangzhou Bay New Zone, Ningbo, China 315936
Since China’s reform and opening up, as one of the first coastal open cities, cities specifically designated in the state plan and sub-provincial cities, Ningbo has witnessed rapid and sustained development, registered tremendous vitality and potential, and became one of Chinese cities with higher level of economic development.

改革开放以来，作为中国首批沿海开放城市、计划单列市和副省级城市，宁波经济持续快速发展，显示出巨大的活力和潜力，是中国经济发展水平较高的城市之一。

Ningbo International Investment Promotion Bureau

Affiliated to Ningbo Municipal Commission of Commerce, Ningbo International Investment Promotion Bureau is a government agency in charge of bilateral investment promotion of Ningbo. We are committed to attract international investment and facilitate local companies to invest overseas, and providing companies with premium "one-stop" investment consultation service.

Ningbo International Investment Promotion Bureau belongs to Ningbo Municipal Commission of Commerce and is responsible for the bilateral investment promotion work, providing companies with "one-stop" investment consultation service.

- GDP of 2015 is USD 130 billion
  2015年全市GDP1300亿美元

- Per capita GDP of 2015 is USD 16,453
  2015年全市人均GDP16453美元

- Total financial revenue of 2015 is USD 33.195 billion
  2015年全市地方财政总收入331.95亿美元

- Trade import and export volume of 2015 is USD 100.466 billion
  2015年全市进出口总额1004.66亿美元

Wendy Zheng

Zheng Wei

Director

Kan Chen

Senior Project Manager

Ningbo International Investment Promotion Bureau

Office 12F, Block A, Development Building, No.111, Hai Street, Ningbo, China (315088)

Tel: +86-574-87310992
Fax: +86-574-87310992
E-mail: wendy.zheng@nptbchina.com
Website: www.nptbchina.com

Ningbo International Investment Promotion Bureau

Office 12F, Block A, Development Building, No.111, Hai Street, Ningbo, China (315088)

Tel: +86-574-87370851
Fax: +86-574-87370851
E-mail: kan.chen@nptbchina.com
Website: www.nptbchina.com
A passion for helping innovative companies succeed is what drives us.

Our global Life Sciences Practice is comprised of 180 corporate, transactional, IP and trial attorneys around the world who share the drive our clients have for scientific and business success.

www.mofo.com/lifesciences

©2016 Morrison & Foerster LLP
Innovations and discoveries in areas such as biologics and biosimilars, bio-agriculture, diagnostic testing, and drug development have turned the promise of biotechnology into reality. Strong intellectual property protection has been essential to the advancement of the industry and remains key to its continued growth.

Finnegan has advised biotech pioneers on every aspect of IP. Let our experience assist you in developing an IP strategy for your biotechnology business.

To learn more, contact partner Tom Irving at info@finnegan.com.
淄博高新区技术产业开发区

Zibo National New and Hi-tech Industrial Development Zone

淄博高新区位于山东省中部，是1992年11月国务院批准设立的国家级高新区，辖区总面积121平方公里。淄博高新区被先后认定为国家新材料、先进陶瓷、功能玻璃、生物医药、创新药物孵化等特色产业基地，正在建设国家创新型科技园区、知识产权试点园区，在129个国家高新区中创新能力评价位居30位。淄博高新区正逐步成为鲁中地区高新技术产业发展的示范区，自主创新引领区、科技创业的核心区。近年来，投资30余亿元，建成了一批综合孵化器，生物医药、精细化工和高分子、先进陶瓷、电子信息、先进制造等五个专业孵化器，淄博瀚海硅谷科技园、淄博瀚海慕尼黑科技园、台北齐鲁科技园三个海外孵化器，总面积达110万平方米，其中国家级孵化器5个；投资3亿多元高标准建设了MEMS研发中试、生物医药、精细化工和高分子材料、无机非金属材料、电子信息五大公共服务平台，创新平台建设走在全国高新区前列。各类孵化器共入驻企业及机构502家，入驻率达80%以上，五大技术平台为1400余家企业提供25000余次检测服务。

生物医药产业是淄博高新区重点发展的新兴产业，依托生物医药公共技术服务平台，高新区管委会与山东大学合作建设了山东大学淄博生物医药研究院，下设药物分析检测中心、技术资料信息查询中心、生物药物实验室、化学药物实验室、天然药物实验室、药物制剂实验室等六个功能单元，拥有大中型仪器设备487台（套），仪器设备总投资4600余万元，已建立起完善的生物医药“技术研发服务链”与“成果转化链”。在区域经济发展中，承担着医药科技成果转移与转化、公共服务服务、实用型技术人才培养、科技交流与合作等多方面职能。同时，高新区企业在消毒灭菌设备、放射治疗系统、制药装备等医疗器械和解热镇痛药、头孢类抗生素、中药等新医药领域保持国内领先地位，拥有新华制药、新华医疗、德贝朗、中化帝斯曼、金城柯瑞、世博金都等一批骨干企业。
Company Overview

Located in Chengdu, China, Chengdu Kanghong Biotech Co is one of the 7 subsidiaries of the 20-year-old Chengdu Kanghong Pharmaceutical Group Co. It is a leading biopharmaceutical company in China, which specializes in the discovery, development, manufacture, and marketing of innovative biologics. Its first biologics, Conbercept, is a novel anti-VEGF (Vascular Endothelial Growth Factor) agent. This is a recombinant fusion protein, including the domain 2 of VEGF receptor (VEGFR)-1, domain 3 and 4 of VEGFR-2, plus human IgG Fc fragment. Conbercept has high VEGF binding affinity, is a 100% humanized protein, and can target multiple VEGF subtypes, including VEGF-A, VEGF-B and PIGF. After 5 clinical trials were successfully finished, Conbercept Ophthalmic Injection was approved to treat Neovascular Age-Related Macular Degeneration (wet AMD) by the CFDA in December, 2013, and launched in China market in March, 2014. Now other indications in ophthalmology, such as Myopic Choroidal Neovascularization (mCNV), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO) are under late-stage clinical development. Conbercept has demonstrated well-tolerated safety profile and superior efficacy, and has been well received in the Chinese market. Holding strong global IP protection, Chengdu Kanghong Biotech is actively pursuing expansion of Conbercept into global market. Meanwhile, Chengdu Kanghong Biotech has a strong pipeline in R&D including KH903 for the treatment of different tumors, and KH906 for the treatment of neovascularization corneal diseases.

Website: www.cnkh.com
Tel: +86-28-87509966
We chat:
Shooting for the **Stars**

Proudly serving clients worldwide with high quality integrated biopharmaceutical services over 10 years

- Flexible Service Models
- Integrated Services
- Preclinical Development
- Biology
- Chemistry & CMC

www.medicilon.com

---

**Pharmaron** is a premier drug discovery and development service provider for life-science industry. Founded in 2003, Pharmaron has established comprehensive and integrated R&D service platforms along with over 3000 staff.

**Mission:** Help our partners accelerate their drug discovery and development programs from early discovery phase all the way to clinical development.

**Service Platform:**
- Chemistry: Discovery chemistry, Medicinal Chemistry, $^{14}$C & $^3$H radiolabeling & CMC
- *In vitro* and *in vivo* DMPK as well as bioanalytical sciences
- Biology and Pharmacology (oncology, metabolic, CNS, and inflammation)
- Safety assessment (FDA inspected and China CFDA GLP certified)

---

**Contact**
Connie Sun
Pharmaron, Inc.
Phone: 650.799.2416
connie.sun@pharmaron.com
科伦是中国十大药企之一，2015年销售额超390亿元，吸引了多位来自BMS, Merck, Abbott, Regeneron, Pfizer, Biogen, Eli Lilly, JNJ, Sanofi, Boehringer Ingelheim, Teva等优秀领军人物加盟。也在美国设立了涉及小分子和大分子领域的研发中心。

中美领军职位空缺: https://kluspharmainc.gethired.com/ 生物药：杂交瘤\textsuperscript{a}，Phage Display\textsuperscript{a}，培养基开发\textsuperscript{b}，细胞培养，工艺，纯化，活性测定，制剂，分析。小分子创新和仿制：计算化学，DMPK, pharmacology, toxicology，合成工艺，制剂，分析，纳米粒，脂质体，微球。临床研究和数据管理。原料药合成和DMF\textsuperscript{b}。

Email 简历和职位给 hr@kluspharma.com

Bio-Thera (www.bio-thera.com)，一个新兴的生物技术公司，在广州，中国，致力于研究和开发新的治疗药物，治疗癌症，炎症，心血管疾病和其他危及生命的疾病。公司的产品管线包括生物类似物和创新抗体药物。今天，有四款候选产品处于各种临床和多个候选药物的不同阶段，研究有巨大的潜力，仍然有许多挑战需要完成。公司正在寻找具有潜力的领导者担任管理职位。

Bio-Thera provides a competitive benefit package. Thank you for sending your CV at hr@bio-thera.com.

For Business collaboration or others, please contact at bd@bio-thera.com.
Your Single Source to Advance Your Research

- Overnight Sanger DNA sequencing
- Gene synthesis for complex constructs
- Next generation sequencing & Bioinformatics solutions
- Full scale plasmid DNA preparations

Gain project efficiencies with timely and accurate data, flexible options, and Ph.D. technical support.

Ask About Special Offers for Bay Area Customers!

Karen Luke
District Sales Manager
T: 510-303-9209
Karen.Luke@GENEWIZ.com
www.geneviz.com

JOINN Innovation Park
Biotech Acceleration Campus

- Preclinical efficacy services
- Customized Animal models
- Biological drug R&D
- Small molecule drug R&D
- Antibody R&D
- Stem Cell
- Cell Therapy and CAR-T
- Pathology and Tissue array
- Cancer Diagnostics
- Medical Devices

Research Labs
Animal Facility
GMP Facility

We can deliver:
- Product design
- Mold Design
- Material Optimization
- Injection molding
- Package
- Prototype
- Integrity and safety testing

1633, Bayshore Hwy, STE
Burlingame CA 94010
Email: info@cosmobrand.com
www.cosmobrand.com

CABS Sponsorship Benefits:

- Access to large pool of high profile members in various fields of Life Sciences
- Gain exposure through promotion at many CABS events, various publication materials, and Internet
- Establish close relations and boost business opportunities with hundreds of other pharmaceutical and biotechnology companies in both US and China
- Receive tax deduction for your financial contribution

Contact: fundraising@cabsweb.org
Conference Notes
Conference Notes
CABS Membership Benefits

• Participate in activities and events organized by CABS and our alliances
• Significant discounts for CABS event registrations, including the BioPacific Conference
• Complimentary participation to many CABS programs including the highly popular CABS Career Advisory Network (CAN) program and the CABS Delegation to China
• Active engagement by volunteering to help organizing our events
• Leadership opportunity by joining our Executive Council

Join CABS Today at: http://www.cabsweb.org/members/

<table>
<thead>
<tr>
<th>Membership Options</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Membership for 1 year</td>
<td>$30</td>
</tr>
<tr>
<td>Regular Membership for 2 year</td>
<td>$50</td>
</tr>
<tr>
<td>Life Time Membership</td>
<td>$300</td>
</tr>
</tbody>
</table>

CABS Sponsorship Benefits

• Access to large pool of high profile members in various fields of Life Sciences
• Gain exposure through promotion at many CABS events, various publication materials, and Internet
• Establish close relations and boost business opportunities with hundreds of other pharmaceutical and biotechnology companies in both US and China
• Receive tax deduction for your financial contribution

Sponsor our CABS events by contacting: fundraising@cabsweb.org or go to http://www.cabsweb.org/sponsors/ for details.

<table>
<thead>
<tr>
<th>Sponsored Content</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Job posting at cabsweb.org (2 months)</td>
<td>$100 per job (1-5 jobs)</td>
</tr>
<tr>
<td></td>
<td>$600 total (5-10 jobs)</td>
</tr>
<tr>
<td></td>
<td>Contact <a href="mailto:president@cabsweb.org">president@cabsweb.org</a> for price (&gt;10 jobs)</td>
</tr>
<tr>
<td>Company logo at cabsweb.org (2 months)</td>
<td>$50 per logo</td>
</tr>
<tr>
<td>Company logo in CABS weekly newsletter</td>
<td>$50 per logo per newsletter</td>
</tr>
</tbody>
</table>
BioPacific Conference 2016
18th CABS Annual Conference
May 7th, Saturday, 2016, 8:00AM-9:00PM
San Mateo Marriott, 1770 South Amphlett Blvd.
San Mateo, CA 94402

Inaugural BioPacific Partnering Forum 2016
May 7 from 9am – 6pm onsite at the 2016 BioPacific Conference
May 8 from 10am – 5pm
Hanqi Investment Inc.
1633 Bayshore Hwy, Burlingame, CA 94010

Who We are
• A professional non-profit organization based in the San Francisco Bay Area
• Over 3,000 members and participants
• Members from US, China and Pacific Rim Countries

Our Mission
• To serve biopharmaceutical professionals with professional interests and promote professional interactions locally and across the Pacific
• To foster business opportunities and exchanges in the life science industry between the U.S. and China
• To promote public awareness of progress and development in the pharmaceutical and biotechnological industry